X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-08-07 | GLYC | Invus Public Equities, L.P. | 10% | S - Sale | $0.19 | -322,361 | 6,317,565 | -5% | -$61,206 | |||||
| M | 2024-08-05 | GLYC | Invus Public Equities, L.P. | 10% | S - Sale | $0.19 | -220,255 | 6,639,926 | -3% | -$41,184 | |||||
| M | 2024-08-01 | GLYC | Invus Public Equities, L.P. | 10% | S - Sale | $0.20 | -349,764 | 6,860,181 | -5% | -$71,097 | |||||
| M | 2024-07-26 | GLYC | Invus Public Equities, L.P. | 10% | S - Sale | $0.23 | -1,379,119 | 7,209,945 | -16% | -$315,262 | |||||
| M | 2024-06-20 | GLYC | Rock Edwin | Chief Medical Officer | P - Purchase | $0.26 | +305,000 | 680,403 | +81% | +$78,825 | |||||
2024-06-18 | GLYC | Hahn Brian M. | SVP Finance, CFO | P - Purchase | $0.25 | +17,500 | 70,643 | +33% | +$4,335 | ||||||
| M | 2023-09-21 | GLYC | Rock Edwin | Chief Medical Officer | P - Purchase | $1.38 | +65,403 | 375,403 | +21% | +$90,256 | |||||
2023-05-17 | GLYC | Hahn Brian M. | SVP Finance, CFO | S - Sale | $1.95 | -3,700 | 53,143 | -7% | -$7,215 | ||||||
2023-05-10 | GLYC | Junius Daniel M | Dir | P - Purchase | $1.56 | +30,000 | 93,250 | +47% | +$46,800 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |